Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Patterson

Allergy & Immunology Noblesville, IN Medical Doctor

NPI 1922001007 CMS profile 268871

14540 Prairie Lakes Blvd N, Suite 207, Noblesville, IN 46060

Open in the dashboard

General payments

$251,797

701 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$5,022

2 holdings reported · through program year 2025

Through program year 2025, David Patterson of Noblesville, IN is reported in the CMS Open Payments database as having received $251,797 across 701 general payments and $0 in research payments paid to them. They also declared ownership or investment interests valued at $5,022 across 2 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,091 63
2024 General $7,142 51
2023 General $5,929 68
2022 General $44,600 106
2021 General $78,477 141
2020 General $28,836 99
2019 General $84,722 173
2025 Ownership $2,511 1
2024 Ownership $2,511 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Patterson
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to David Patterson were reported at $2,091. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year David Patterson Allergy & Immunology median Middle half National median
2019 $84,722 $594 $163–$1,512 $163
2020 $28,836 $426 $106–$1,233 $114
2021 $78,477 $638 $157–$1,708 $132
2022 $44,600 $790 $205–$1,961 $149
2023 $5,929 $852 $220–$2,147 $160
2024 $7,142 $865 $203–$2,267 $164
2025 $2,091 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Regeneron Healthcare Solutions, Inc. $142,624 195 payments
  2. Genzyme Corporation $89,225 123 payments
  3. GlaxoSmithKline, LLC. $4,602 99 payments
  4. ADMA BioManufacturing LLC $3,262 5 payments
  5. Pharming Healthcare, Inc. $3,065 16 payments
  6. Grifols USA, LLC $1,959 17 payments
  7. Consortium of Independent Immunology Clinics, LLC $1,516 3 payments
  8. AstraZeneca Pharmaceuticals LP $1,208 66 payments
  9. Octapharma USA, Inc. $1,143 15 payments
  10. Novartis Pharmaceuticals Corporation $273 14 payments
  11. Other $2,921 148 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $203,301 98 payments
  2. Travel and Lodging $22,488 90 payments
  3. Food and Beverage $11,431 498 payments
  4. Consulting Fee $11,218 8 payments
  5. Honoraria $3,250 2 payments
  6. Education $109 5 payments
Products named General payments · program years 2019–2025
  1. DUPIXENT Inflammation And Immunology $142,193 195 payments
  2. DUPIXENT Immunology $82,082 156 payments
  3. DUPIXENT Immunology $15,766 23 payments
  4. JOENJA $2,787 4 payments
  5. Xembify $1,843 11 payments
  6. CUTAQUIG $1,098 14 payments
  7. NUCALA Immunology $669 40 payments
  8. NUCALA Respiratory $654 16 payments
  9. TRELEGY ELLIPTA $533 39 payments
  10. FASENRA $390 22 payments
  11. Other $4,233 229 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

583

Median for Allergy/ Immunology: 449

Drug cost

$536,266

Median for Allergy/ Immunology: $169,700

Branded share of claims

65.2%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hizentra Immun Glob G(Igg)/Pro/Iga 0-50 Brand 83 $331,217
Cuvitru Immun Glob G(Igg)/Gly/Iga Ov50 Brand 26 $85,548
Gammagard Liquid Immun Glob G(Igg)/Gly/Iga Ov50 Brand 26 $26,901
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 20 $19,425
Xhance Fluticasone Propionate Brand 12 $14,739
Arnuity Ellipta Fluticasone Furoate Brand 41 $14,288
Breo Ellipta Fluticasone/Vilanterol Brand 22 $12,450
Spiriva Respimat Tiotropium Bromide Brand 21 $11,074
Advair Hfa Fluticasone Propion/Salmeterol Brand 16 $8,191
Epinephrine Generic 16 $2,812

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 30 billing codes

Paid by Medicare

$836,917

Of which drugs: $780,369

Medicare patients

229

Average age 72

Services billed

41,691

166 women, 63 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 59%
Arthritis 54%
Osteoporosis 22%
Depression 21%
Ischemic heart disease 20%
Diabetes 18%
Chronic kidney disease 15%
COPD 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, omalizumab, 5 mg J2357 Office 11 6,540 $194,515

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $2,132
  • GENZYME CORPORATION $33
$2,165 — —
NUCALA
  • GlaxoSmithKline, LLC. $176
$176 — —
RUCONEST
  • Pharming Healthcare, Inc. $87
$87 — —
FASENRA
  • AstraZeneca Pharmaceuticals LP $85
$85 — —
CUTAQUIG
  • Octapharma USA, Inc. $58
  • PFIZER INC. $6
$64 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

701 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record